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“The 3rd annual conference - Ortho posturo gnosis – the knowledge to influence 
and control the disease” took place in Iasi during the 4Th of December, 2010, 
addressed to all of the doctors which contributed to this scope for therapy 
(neurologists cardiologists, rehabilitative in medicine, reumathologists, 
neurosurgeons, orthopedists etc). 
The theme of this year was interesting and promising field for the future of the 
medicine: Rehabilitative medicine – progress and promise of regenerative medicine: 
from molecule to society. 
We choose from the conference same specials lectures which were selected by the 
Scientific Committee. 
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Progress and promise of Regenerative Medicine – Molecule to 
Society 
E.A. Traboulay, Jr. 
 
Introduction  
On this auspicious occasion of 
celebration I take this opportunity to make 
a brief presentation on the theme of this 
conference - the knowledge to influence 
and control diseases – as it applies to my 
field of biotechnology. An intriguing 
question that we can ask is how can we use 
regenerative medicine to increase lifetimes 
while allowing us to age gracefully? In my 
presentation I will provide some 
interventions and try to cover the following 
topics: 1) the history of tissue and organ 
regeneration; 2) approaches to regenerative 
medicine; 3) current clinical trials 
underway; 4) current research projects in 
my laboratory and 5) some economic 
factors influencing our industry. 
What exactly is regenerative medicine? 
The origins of regenerative medicine are 
based in Greek mythology and I am sure 
evidence can be found elsewhere in other 
civilizations. As the story goes, Zeus, who 
was the supreme ruler of the 12 gods on 
Mount Olympus, was upset that 
Prometheus gave the technology of making 
“fire” to the Greeks. To punish 
Prometheus, Zeus ordered him tied to a 
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rock and sent an eagle to eat his liver each 
day. Well Prometheus was able to survive 
the ordeal because his liver was able to 
regenerate itself daily. Fortunately today we 
still have that regenerative ability to some 
extent. 
To begin it is necessary to define 
regenerative medicine as it has different 
meanings to different people. This is 
because the field has become populated 
with engineers, physicists, 
biopolymer/biochemists, molecular 
biologists, mathematicians, 
nanotechnologists and computer specialists 
bringing diverse tools such as finite element 
analysis and computer aided designs to 
create scaffolds and a host of bio-materials 
for use in regenerative medicine. So today 
we can define regenerative medicine as 
“understanding the body’s healing process 
and speeding-up that process to a clinically 
acceptable time scale or outcome.” This 
involves using stem cell therapy, 
regenerative factors, specific acellular 
scaffolds, therapeutic cloning and finally 
integration in-vivo of the organ or tissue to 
affect a regenerative outcome in a patient. 
Despite having some 100 trillion cells, the 
human body is very poor at repair as we 
seem to be in acute or chronic decline 
through disease, trauma or aging. The 
“Holy Grail” of regenerative medicine 
would be the duplication in humans the 
regenerative power of amphibians like the 
salamander which can regenerate an 
amputated limb in 70-days1. 
The history of tissue and organ 
regeneration 
As we survey the historical medical 
landscape we see interesting “tipping-
points” occurring every 100 years or so that 
have transformed the way doctors treat 
patients and the resulting improvement in 
successful outcomes. The giants like 
Pasteur, Lister and Koch led a revolution in 
modern medicine. However, it took 
another 100 years before 
immunosuppressive drugs became available 
to doctors and then we saw a flurry of organ 
transplants between 1954 and 1967 – liver, 
lung, pancreas and heart. In the 90’s we 
were fascinated with Wilmot’s somatic cell 
nuclear transfer cloning of “Dolly.” Bio-
techniques have been developed to 
quantitatively decellularize complex organs 
such as heart, liver, and kidney. These 
acellular matrices can provide attractive 
scaffolds for repopulation with the 
recipient’s own cells for tissue engineering 
as the extracellular matrix template contains 
appropriate three-dimensional architecture 
and regional-specific cues for cellular 
adhesion. In 2006 this work was pioneered 
by Atala2 whose tissue engineered bladder 
was successfully transplanted using the 
patient’s own cells without antigenicity.  
In 2008 Macchiarini3 and his 
multinational team at the University of 
Barcelona was the first to have successfully 
transplanted a trachea into a patient, with 
end-stage airway disease, without 
antigenicity. The patient presented with 
dysphonia and cough due to tuberculosis 
infiltration of the cervical trachea and entire 
left main bronchus. A CT scan showed a 
circumferential, near-occlusive 3 cm airway 
stenosis starting 2 cm subglottically, and a 
hypoplastic left main bronchus with 
expiratory collapse. Macchiarini removed 
cells and the major histocompatibility 
complex (MHC) antigens from a human 
donor trachea (cadaver), which was then 
readily colonized by epithelial cells and 
mesenchymal stem-cell-derived 
chondrocytes that had been cultured from 
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cells taken from the recipient bone marrow. 
This graft was then used to replace the 
recipient's left main bronchus. The patient 
is healthy after 4 months and had no anti-
donor antibodies and is not on 
immunosuppressive drugs.  
Approaches to regenerative medicine 
As we step through the frontiers of the 
21st century, we are all witnesses to the 
Cinderella story in the form of the induced 
pluripotent stem cells (iPSC’s). The process 
developed by Yamanaka4 of re-
programming adult somatic cells to derive 
(iPSC’s) with the wand of transcription 
factors (Oct4, Sox2, Klf4, and c-Myc) and 
then differentiating them back to adult 
somatic cells. This is the most fascinating 
breakthrough in regenerative medicine 
since the structure of DNA was elucidated. 
Rossi5 further improved efficiencies by 
developing a non-integrating strategy for 
reprogramming cell fate based on 
administration of synthetic mRNA 
modified to overcome innate antiviral 
responses – no teratomas. 
3.1 Intervention - Bioengineered tooth 
Unlike other vertebrates, mammals can 
replace only their deciduous teeth. During 
mammalian evolution this regenerative 
capacity was lost6. The deterioration and 
loss of teeth that comes with old age affects 
more than smiles. Periodontal disease has 
been associated with increased risk for heart 
disease and might quicken the pace of 
aging. Poor nutrition after tooth loss could 
also cause problems. Etsuko7 led a tooth 
regeneration team that devised an ambitious 
plan that sought to use stem cell biology, 
engineering, and computational biology to 
replicate the developmental program for 
odontogenesis. They proposed a laboratory-
grown tooth rudiment that would be 
capable of executing the complete program 
for odontogenesis when transplanted into a 
mouse host, recreating all of the dental 
tissues, periodontal ligament, cementum, 
and alveolar bone associated with the 
canonical tooth.  
To this end epithelial and mesenchymal 
stem cells were placed within a collagen gel 
and cells were expanded (ex-vivo) for 7-
days to obtain ~200,000 cells which were 
then transplanted with the correct 
orientation into a properly-sized bony hole 
in the upper first molar region of the 
alveolar bone. The results showed that the 
cusp tip of the bioengineered tooth was 
exposed into the oral cavity with full 
occlusion at 36.7± 5.5 days after 
transplantation. A more elegant solution 
would be to design a gene to allow a third 
set of teeth erupting at the age of 55. This 
would be an ingenious fix if we ignore the 
pain some of us experienced with the 
eruption of our molars.  
3.2 Regenerating the articular surface of a 
synovial joint 
Osteoarthritis is a debilitating disease 
that manifests as structural breakdown of 
cartilage and bone that affects over 80 
million individuals in the USA alone8. To 
understand the nature of the problem the 
synovial joint consists of multiple tissues 
including articular cartilage, subchondral 
bone, hematopoietic marrow, and 
synovium making repair somewhat 
problematic. Current therapy requires 
arthritic joints to be replaced by total joint 
arthroplasty using metallic and synthetic 
materials which fail mainly because of 
aseptic loosening or infection induced by 
wear debris9. This is an interesting problem 
that can only be solved by biological 
regeneration. Although stem cell 
transplantation has been tried, the results 
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are mixed for a variety of reasons, with 
some patients finally having joint 
arthroplasty. 
To solve this problem, Jeremy Mao10 
and his team regenerated the articular 
surface of the synovial joint of a rabbit with 
a biological cue spatially embedded in an 
anatomically correct bioscaffold. The 
surface morphology of a rabbit proximal 
humeral joint (cadaver) was captured with 
laser scanning and reconstructed by 
computer-aided design. The team 
fabricated an anatomically correct 
bioscaffold using a composite of poly-e-
caprolactone and hydroxyapatite. The entire 
articular surface of humeral condyles of 
skeletally mature rabbits was surgically 
excised and replaced with the bioscaffolds 
spatially infused with transforming growth 
factor ß3 (TGFß3)-adsorbed or TGFß3-
free collagen hydrogel. Locomotion and 
weightbearing were observed in the test 
rabbits 3–4 weeks after surgery. At 4 
months the entire articular surface of the 
synovial joint was regenerated without cell 
transplantation. Regeneration of complex 
tissues is probably by homing of 
endogenous cells, as exemplified by 
stratified avascular cartilage and vascularised 
bone. 
Clinical Trials 
The first approved U.S. clinical trial to 
use human embryonic stem cells to treat a 
disease has enrolled its first patient. Geron 
Corp., which is sponsoring the trial using 
stem cells to treat spinal cord injury, 
announced that the first patient was treated 
on October 8th 2010 at a hospital in 
Atlanta. The primary objective of this Phase 
I study is to assess the safety and tolerability 
of GRNOPC1 in patients with complete 
American Spinal Injury Association (ASIA) 
Impairment Scale grade A thoracic spinal 
cord injuries. Participants in the study must 
be newly injured and receive GRNOPC1 
within 14 days of the injury. Geron will be 
testing Oligodendrocyte progenitor cells, 
precursors to some nervous system cells the 
company developed from one of the 
original human embryonic stem cell lines 
developed by James Thomson’s lab at the 
University of Wisconsin, Madison. The 
goal is not to create new nerve fibers but to 
support those still intact by making the 
nerve insulator myelin. To prevent 
rejection, patients will take immune-
suppressing drugs for about 60 days. 
Although the primary goal is to assess 
safety, Geron will be looking for hints that 
the cells had an effect—for example, 
improving bladder and bowel function, 
sensation, or mobility. 
Advanced Cell Technology will conduct 
the second FDA approved clinical trial 
using embryonic stem cell–derived retinal 
pigment epithelial cells to treat Stargardt’s 
Macular Dystrophy, a congenital eye 
disease. The company is also filing an 
application to try the treatment in age-
related macular degeneration, a disease with 
similar characteristics that affects as many as 
30 million people in the United States and 
Europe. Cell therapy seems promising for 
the disease for several reasons. First, the eye 
is an immune-privileged site, so researchers 
hope that patients won't have to take 
antirejection drugs after receiving the 
transplant. Second, because the retina can 
be observed at the single cell level it should 
be possible to follow the transplanted cells' 
behavior very precisely. The patients will 
receive up to 200,000 retinal pigment 
epithelium (RPE) cells that the company 
derived from hES cells, transplanted 
directly into the eye. 
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Our Laboratory 
Our laboratory is specialized in the 
isolation, expansion and cryostorage of stem 
cells obtained from umbilical cord blood, 
Wharton’s Jelly, deciduous teeth and 
adipose tissue. We are currently in the 
process of making therapeutic doses for 
sale. Our laboratory (450 m2) has clean 
rooms and is fully certified having ISO 
14644-1/1999, ISO 14644-2/2000, ISO 
14644-3/2005, ISO 9001:2008, FDA/GMP 
Annex1/2003 with FACT-NETCORD 
pending. 
Although this is a hybrid commercial 
laboratory, we have embarked on a modest 
research project to regenerate the retina in 
patients suffering from trauma, disease and 
age-related loss of vision using autologous 
mesenchymal stem cells. This is a joint 
project with Prof. Fotiadiou at the 
University of Basel, Switzerland and local 
Greek ophthalmologists. Hopefully at our 
next meeting I would be able to report 
some results. 
Economic Considerations 
In the US it is generally believed that 
there are approximately 1.400 biotech 
laboratories with approximately 300 traded 
on Wall Street. These companies have 
produced over 200 approved therapies 
using stem cells which have been approved 
in the US, Europe and Australia. The 
geographical split of the biotech market in 
2004 shows the US accounting for 59.6% of 
the global market, or $26.4bn, around 2.8 
times the total combined sales in the top 
five European countries – France ($2.4 
billion), Germany ($2.8 billion), Italy ($1.6 
billion), Spain ($1.3 billion) and the UK 
($1.2 billion). The rest of the world 
estimated at $5.5 billion. This is a 
significant difference considering that a 
similar number of products were available 
in both regions at any given time. The total 
worth of the Global biotech market in 2004 
was $44.3 billion11. 
I have performed a more comprehensive 
analysis of the global biotech market for 
2009 and the results show an impressive 
gain of 122% in the 5-year period 
amounting to $98.7 billion – see Table 1. 
 
TABLE 1 
Global biotech market 
Global Biotech Market 2009 
Technology 2009 (US Mill $) 
Stem cell transplant 9.250 
Cord blood collection and 
Storage 
1.800 
Tissue engineering 25.500 
Blood transfusion products 36.000 
Cell-based gene therapy 9.000 
Encapsulated cell therapy 2.700 
Cell-based cancer vaccines 2.200 
Xenotransplantation 2.700 
Supporting technologies:  Cell 
lines, cell culture, delivery 
devices 
9.563 
 
Total 98.713 
 
 
In summary, I believe that in the future 
is bright for biotechnology companies 
allowing us to gain the knowledge to 
influence and control diseases.  In 2011 we 
will see the cost for a personal genome 
analysis below $1.000 and results taking less 
than one week.  This will open a new field 
that will allow nanotechnology to design 
robots to repair our DNA before the onset 
of debilitating diseases.  Furthermore in the 
very near future, it will be possible for every 
person to have their own iPS cell lines, 
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prepared when they were still healthy, for 
future applications in clinical examination 
and/or therapy. 
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